U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
99264
Substance Class Protein
Created
by admin
on Mon Oct 21 20:01:17 UTC 2019
Edited
by admin
on Mon Oct 21 20:01:17 UTC 2019
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
VK4SQL11C0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTOCHROME P450 1A2
Common Name English
CYTOCHROME P450-P3
Common Name English
CYP1A2
Common Name English
CYTOCHROME P(3)450
Common Name English
HUMAN CYTOCHROME P450 1A2
Common Name English
CYTOCHROME P 450 1A2
Common Name English
Code System Code Type Description
CAS
165885-24-5
Created by admin on Mon Oct 21 20:01:17 UTC 2019 , Edited by admin on Mon Oct 21 20:01:17 UTC 2019
PRIMARY
UNIPROT
P05177
Created by admin on Mon Oct 21 20:01:17 UTC 2019 , Edited by admin on Mon Oct 21 20:01:17 UTC 2019
PRIMARY
PUBCHEM
121225712
Created by admin on Mon Oct 21 20:01:17 UTC 2019 , Edited by admin on Mon Oct 21 20:01:17 UTC 2019
PRIMARY
Related Record Type Details
Structure of PHENACETIN
SUBSTRATE -> METABOLIC ENZYME
Structure of TAFENOQUINE
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of DEFERASIROX
SUBSTRATE -> METABOLIC ENZYME
Structure of OLANZAPINE
SUBSTRATE -> METABOLIC ENZYME
Structure of RUCAPARIB
INHIBITOR -> METABOLIC ENZYME
REVERSIBLE
Structure of STIRIPENTOL
INHIBITOR -> METABOLIC ENZYME
Structure of SONIDEGIB
NON-INDUCER -> METABOLIC ENZYME
compared to positive controls
Structure of TERIFLUNOMIDE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of DAPTOMYCIN
NON-INHIBITOR -> METABOLIC ENZYME
Structure of PF-06650833
NON-INHIBITOR -> METABOLIC ENZYME
Structure of CAFFEINE
SUBSTRATE -> METABOLIC ENZYME
Structure of TACRINE
SUBSTRATE -> METABOLIC ENZYME
Structure of PIRFENIDONE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of GNE-0877
INHIBITOR -> METABOLIC ENZYME
HM-43239
SUBSTRATE -> METABOLIC ENZYME
Structure of LANSOPRAZOLE
INDUCER -> METABOLIC ENZYME
Structure of LORCASERIN
SUBSTRATE -> METABOLIC ENZYME
Structure of TRICLABENDAZOLE SULPHONE
INHIBITOR -> METABOLIC ENZYME
Structure of NAPROXEN
SUBSTRATE -> METABOLIC ENZYME
Structure of CIMETIDINE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of DEUTETRABENAZINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of LOMITAPIDE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of ZOLPIDEM
SUBSTRATE -> METABOLIC ENZYME
Structure of FLIBANSERIN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of ENASIDENIB
SUBSTRATE -> METABOLIC ENZYME
Structure of WARFARIN, (R)-
SUBSTRATE -> METABOLIC ENZYME
Structure of CIPROFLOXACIN
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of ENZALUTAMIDE
INHIBITOR -> METABOLIC ENZYME
TIME-DEPENDENT INHIBITION
HUMAN LIVER
TISSUE EXPRESSION -> PARENT
Structure of LOFEXIDINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of BRANEBRUTINIB
INHIBITOR -> METABOLIC ENZYME
Structure of TIZANIDINE
SUBSTRATE -> METABOLIC ENZYME
Structure of OXYMETAZOLINE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of DAPSONE
SUBSTRATE -> METABOLIC ENZYME
Structure of ELTROMBOPAG
SUBSTRATE -> METABOLIC ENZYME
Structure of IMIPRAMINE
SUBSTRATE -> METABOLIC ENZYME
Structure of TRICLABENDAZOLE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of TRICLABENDAZOLE SULPHOXIDE
INHIBITOR -> METABOLIC ENZYME
Structure of AMIODARONE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of FEBUXOSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of RUCAPARIB
INDUCER -> METABOLIC ENZYME
Structure of VERUBECESTAT
NON-INHIBITOR -> METABOLIC ENZYME
Structure of CLOZAPINE
SUBSTRATE -> METABOLIC ENZYME
Structure of VERUBECESTAT
NON-INDUCER -> METABOLIC ENZYME
Structure of ACETAMINOPHEN
SUBSTRATE -> METABOLIC ENZYME
Structure of FLUVOXAMINE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of ASENAPINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of RIFAMYCIN
INHIBITOR -> METABOLIC ENZYME
Rifamycin is an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose clinically relevant inhibition of these enzymes in vivo is unlikely.
Structure of IXAZOMIB
SUBSTRATE -> METABOLIC ENZYME
Structure of VOXILAPREVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of 2-(3-FLUOROPHENYL)-5-HYDROXY-6-METHOXY-4(1H)-QUINOLINONE
INHIBITOR -> METABOLIC ENZYME
Structure of CARBAMAZEPINE
INDUCER -> METABOLIC ENZYME
Structure of OBETICHOLIC ACID
INHIBITOR OF EXPRESSION->METABOLIC ENZYME
The effect of 10 mg OCA on CYP1A2 substrate caffeine showed that systemicexposure to caffeine increased by 42%. The systemic exposure to caffeine increased by 65% following 25 mg OCA.
Structure of RASAGILINE
SUBSTRATE -> METABOLIC ENZYME
Structure of CRISABOROLE
SUBSTRATE -> METABOLIC ENZYME
Structure of COBICISTAT
NON-INHIBITOR -> METABOLIC ENZYME
Structure of RAMELTEON
SUBSTRATE -> METABOLIC ENZYME
Structure of RIFAMPIN
INDUCER -> METABOLIC ENZYME
POTENT
Structure of ENCORAFENIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of OMEPRAZOLE
INDUCER -> METABOLIC ENZYME
Structure of CYCLOBENZAPRINE
SUBSTRATE -> METABOLIC ENZYME
Structure of POMALIDOMIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of PF-06821497
NON-INHIBITOR -> METABOLIC ENZYME
Structure of GABAPENTIN ENACARBIL
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of TASIMELTEON
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of TETRABENAZINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of SONIDEGIB
NON-INHIBITOR -> METABOLIC ENZYME
No time dependent inhibition upto 50 micromolar
Structure of GNE-0877
INDUCER -> METABOLIC ENZYME
Structure of PALONOSETRON
SUBSTRATE -> METABOLIC ENZYME
Structure of RUCAPARIB
SUBSTRATE -> METABOLIC ENZYME
In vitro, rucaparib was metabolized primarily by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4.
Structure of BINIMETINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of DACARBAZINE
SUBSTRATE -> METABOLIC ENZYME
Structure of ROFLUMILAST
SUBSTRATE -> METABOLIC ENZYME
Structure of THEOPHYLLINE
SUBSTRATE -> METABOLIC ENZYME
Structure of APREPITANT
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of TRICLABENDAZOLE
INHIBITOR -> METABOLIC ENZYME
Structure of DULOXETINE
SUBSTRATE -> METABOLIC ENZYME
Structure of EDARAVONE
INDUCER -> METABOLIC ENZYME
Edaravone inhib it e d CYP2C9, BCRP, OAT3, and induced CYP1A2 in vitro.
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966